2025 second_quarter Filing
Q2Income
$80K
Filed
July 16, 2025
Lobbying Activities
Health IssuesView all
Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.
Contacted:HOUSE OF REPRESENTATIVES, SENATE
Lobbyists (3)
ROBERT CLAYTON ALSPACH
Chief Health Counsel for Chairman - House E&C Committee (E&C);Counsel - E&C, Clerk - E&C, and Paid Intern - E&C
JOSH TRENT
Chief Health Counsel for Chairman - House E&C Committee (E&C); Deputy Chief Health Counsel - E&C; Professional Staff - E&C; Health Care Policy Advisor - Senate; Deputy Director Office of Refugee Resettlement HHS; WH Office of Presidential Personnel
mrs SHANNON ROHN DEERE